跳至主要内容
临床试验/CTRI/2022/07/043705
CTRI/2022/07/043705尚未招募2 期

An Open label Multicentre Clinical Study to Evaluate the Oral Safety and Efficacy of Himalaya Botanique Whitening Complete Care Toothpaste Simply mint and Himalaya Botanique Whitening Complete Care Toothpaste Simply peppermint in Healthy Adult Subjects

Himalaya wellness company0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Subjects with age group 18 years to 60 years in general good health and oral health and are willing to provide consent to the study
  • 2.Subjects with moderate oral hygiene and adhering to basic habits like using standard brush paste
  • 3.Subjects with extrinsic tea, coffee, tobacco and smoking stains on the teeth
  • 4.No history of any clinically significant medical condition
  • 5.No history of any medical problems requiring hospital care
  • 6.Willing to abide by and comply with the study protocol
  • 7.Available to comply the study procedure for the entire duration of the study.
  • 8.Should not have participated in a similar investigation in the past four weeks and who are willing not to participate in any other clinical study during participation in the current study

排除标准

  • 1.A known history or present condition of hypersensitivity to any test product
  • 2.Pregnant and lactating subjects
  • 3.The use of antibiotic, antimicrobial, analgesic medications, desensitizing test product during the previous 1 month
  • 4.Any history of periodontal therapy by surgical interventions
  • 5.Any history of dentine hypersensitivity treatment
  • 6.Any removable appliances such as a removable partial denture or orthodontic retainer
  • 7.Having intrinsic dental stains
  • 8.Having Chronic Generalized Periodontitis
  • 9.Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of currently using any medication or expects to be on any medication which in the opinion of the investigator, may affect the evaluation of the test product, or place the subject at undue risk

研究者

相似试验

招募中
3 期
A Phase 3 study of the digital therapeutics CA-NASH in patients with Nonalcoholic Steatohepatitis (NASH)on-alcoholic Steatohepatitis
JPRN-jRCT2032230595echi Tatsuya346
进行中(未招募)
1 期
An open-label, multi-centre, clinical study to collect information on the clinical use of argatroban in patients with heparin induced thrombocytopenia (HIT) Type II who require parenteral antithrombotic therapy. - ARG-E07
EUCTR2008-000730-42-FRMitsubishi Tanabe Pharma Corporation20
已完成
2 期
Eltrombopag and Early Refractory Immune Thrombocytopenia (ITP)Blood - Haematological diseasesImmune Thrombocytopenia
ACTRN12613000721707Alfred Health39
进行中(未招募)
1 期
Multicenter, randomized, open label study evaluating a poly(ADP-ribose) polymerase-1(PARP-1) inhibitor, SAR240550 (BSI-201), administered twice weekly or weekly, in combination with gemcitabine/carboplatin, in patients with metastatic Triple Negative Breast Cancer (mTNBC)Metastatic Triple Negative Breast Cancer.MedDRA version: 12.0Level: PTClassification code 10055113Term: Breast cancer metastatic
EUCTR2009-016091-80-FRsanofi-aventis recherche & développement80
进行中(未招募)
不适用
Multicenter, randomized, open label study evaluating an anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) monoclonal antibody, AVE1642, administered every 4 weeks in combination with fulvestrant (Faslodex) in postmenopausal patients with advanced hormono-dependent breast cancer - NDAdvanced hormono-dependent breast cancerMedDRA version: 9.1Level: LLTClassification code 10006202Term: Breast cancer stage IV
EUCTR2008-000810-54-ITsanofi-aventis recherche et de'veloppement100